Yes. A few weeks ago. Hard to get approved expensive trials for high cost drugs where for each indication there are multiple competitiors. Not an easily deriskable bet. Everything could work out fine but they could be late to market.
Look at a one-year chart and imagine that the spike to $38 never occurred: imagine that the September high was $28. If that were the case, you'd be loving the way the chart has developed over the past six months. CLDX's chart is strong.
$38 was an illusion a Cramer manufuactured pump job. he then dumped.
quiet until year end rindo results. even then not much action unless along the way AM gets off his high horse and does a PT for 1127.
1135 did not help and it is a black mark against management.
2016 is not that far off.
lets hope nothing pops up by then re competitors for rindo.
The bio mkt. has been taking it in the but it looks like we've bottomed out, and just need to hold our ground for about 5 weeks. The ASCO drift should start, and if things go well we should recover nicely. If things go really well. we'll all be very happy campers. I'm really counting on the 'really well' scenario.